Dennis Horvath

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 9

Top Topics

Prostate Cancer

Lipopolysaccharide Induced

Anti Inflammatory

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Dennis Horvath, Michael Basler
PLGA Particles in Immunotherapy. Pharmaceutics 15 (2) (2023)
Dennis Horvath, Michael Basler
PLGA Particles in Immunotherapy. Pharmaceutics 15 (2) (2023)
Dennis Horvath, Michael Basler
PLGA Particles in Immunotherapy. Pharmaceutics 15 (2) (2023)
Dennis Horvath, Michael Basler
PLGA Particles in Immunotherapy. Pharmaceutics 15 (2) (2023)
Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. Oncoimmunology 12 (1) (2022)
Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. Oncoimmunology 12 (1) (2022)
Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. Oncoimmunology 12 (1) (2022)
Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler
Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition. Oncoimmunology 12 (1) (2022)
Julia Koerner, Dennis Horvath, Valerie L Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, Marcus Groettrup
PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nature communications 12 (1) (2021)